Why the study?
Do clinical risk scores reliably predict recurrent atrial fibrillation after catheter ablation?
Do clinical risk scores reliably predict recurrent atrial fibrillation after catheter ablation?
Answers are grounded in this paper and cite their sources.
Various clinical risk scores exist for predicting AF recurrence after catheter ablation, but they require prospective validation and comparison in independent external cohorts before routine clinical application.
Pulmonary vein isolation (PVI) is a cornerstone of catheter ablation (CA) for atrial fibrillation (AF), but the achievement of durable PVI lesion can be challenging, and PVI alone may be insufficient for successful rhythm control in approximately a third of patients who underwent CA of AF, resulting in a high rate of recurrent atrial arrhythmias post-CA and repeat CA procedures.1 The reliable prediction of post-ablation AF recurrence might facilitate the pre-procedural selection of AF patients eligible for CA and planning of the optimal rhythm monitoring strategy and drug therapy during post-CA follow-up. We have read with great interest the paper entitled ‘Development and validation of a risk score for predicting atrial fibrillation recurrence after a first catheter ablation procedure – ATLAS score’, by Mesquita et al.,2 reporting the Age >60 years, Type of AF, Left Atrial volume indexed by body surface area, female Sex and Smoking (ATLAS) scoring system developed and validated in a multi-centre cohort of patients who undergone AF ablation for predicting recurrent AF post-CA.2 Notably, some of the ATLAS score components, such as normalized left atrial (LA) volume, require additional pre-procedural imaging [i.e. computed tomography (CT)], sophisticated computer software (CARTO electro-anatomical mapping system) and complex calculation, thus making the score less practical in daily practice.2 In addition, CT imaging prior to PVI is performed routinely in 59% of the electrophysiology (EP) centres.1 It would be of interest to see whether the score would also work if a simplified method for LA size measurement (e.g. transthoracic echocardiography) was used. Surprisingly, the Authors identified only two other scores for the prediction of recurrent AF post-CA (i.e. DR-FLASH and CAAP-AF)2 among several recently published scoring tools for recurrent AF post index or redo CA, including the APPLE, ALARMEc, BASE-AF2, and MB-LATER score, as listed in Table 1.3,4 For example, the Male gender, Bundle branch block, Left Atrial diameter ≥47 mm, Type of AF and Early Recurrence of AF, ‘May-Be-LATER’, (MB-LATER) score developed by our group is a clinically based score containing readily available variables.4 Owing to its simplicity, the MB-LATER score is very suitable for a busy outpatient setting in routine clinical practice. Furthermore, the clinical utility of the APPLE, CAAP-AF, and MB-LATER scores has been recently confirmed in external cohorts (pending publication).3–5 The scoring systems for predicting of atrial fibrillation recurrence after catheter ablation2–5 NPAF (1) Normalized LA area ≥10.25 (1) GFR <68 mL/min (1) Metabolic syndrome (1) Cardiomyopathy (1) Age >65 years (1) NPAF (1) eGFR <60 mL/min/1.73 m2 (1) LAD ≥43 mm (1) LV EF <50% (1) Age >60 years (1) NPAF (2) LA volume/m2 (1 point per 10 mL/m2) Female sex (4) Current smoking (7) BMI >28 kg/m2 (1) LAD >40 mm (1) Current smoking (1) ERAF (1) AF history >6 years (1) NPAF (1) Coronary disease (1) LAD (0–4) Age (0–3) NPAF (2) AADs failed (0–2) Female sex (1) Diabetes (1) eGFR <90 mL/min/1.73 m2 (1) NPAF (1) LAD >45 mm (1) Age >65 years (1) Female sex (1) Hypertension (1) Male sex (1) BBB (1) LAD ≥47 mm (1) Type of AF (0-2) ERAF (1) NPAF (1) LA area >21 cm2 (1) Common PV truncus (1) AF history >3 years (1) Female sex (1) NPAF (1) Normalized LA area ≥10.25 (1) GFR <68 mL/min (1) Metabolic syndrome (1) Cardiomyopathy (1) Age >65 years (1) NPAF (1) eGFR <60 mL/min/1.73 m2 (1) LAD ≥43 mm (1) LV EF <50% (1) Age >60 years (1) NPAF (2) LA volume/m2 (1 point per 10 mL/m2) Female sex (4) Current smoking (7) BMI >28 kg/m2 (1) LAD >40 mm (1) Current smoking (1) ERAF (1) AF history >6 years (1) NPAF (1) Coronary disease (1) LAD (0–4) Age (0–3) NPAF (2) AADs failed (0–2) Female sex (1) Diabetes (1) eGFR <90 mL/min/1.73 m2 (1) NPAF (1) LAD >45 mm (1) Age >65 years (1) Female sex (1) Hypertension (1) Male sex (1) BBB (1) LAD ≥47 mm (1) Type of AF (0-2) ERAF (1) NPAF (1) LA area >21 cm2 (1) Common PV truncus (1) AF history >3 years (1) Female sex (1) AAD, antiarrhythmic drug; AF, atrial fibrillation; AUC, area under curve; BBB, bundle branch block; BMI, body mass index; CA, catheter ablation; CFAE, complex fragmented atrial electrograms; CI, confidence interval; ERAF, early recurrence of atrial fibrillation; GFR, glomerular filtration rate; IQR, interquartile range; LA, left atrium; LAD, left atrial diameter; LVEF, left ventricular ejection fraction; MI, mitral isthmus; NA, not available; NPAF, non-paroxysmal atrial fibrillation; PAF, paroxysmal atrial fibrillation; PV, pulmonary vein; PVI, pulmonary vein isolation; RF, radiofrequency; SVCi, superior vena cava isolation. The scoring systems for predicting of atrial fibrillation recurrence after catheter ablation2–5 NPAF (1) Normalized LA area ≥10.25 (1) GFR <68 mL/min (1) Metabolic syndrome (1) Cardiomyopathy (1) Age >65 years (1) NPAF (1) eGFR <60 mL/min/1.73 m2 (1) LAD ≥43 mm (1) LV EF <50% (1) Age >60 years (1) NPAF (2) LA volume/m2 (1 point per 10 mL/m2) Female sex (4) Current smoking (7) BMI >28 kg/m2 (1) LAD >40 mm (1) Current smoking (1) ERAF (1) AF history >6 years (1) NPAF (1) Coronary disease (1) LAD (0–4) Age (0–3) NPAF (2) AADs failed (0–2) Female sex (1) Diabetes (1) eGFR <90 mL/min/1.73 m2 (1) NPAF (1) LAD >45 mm (1) Age >65 years (1) Female sex (1) Hypertension (1) Male sex (1) BBB (1) LAD ≥47 mm (1) Type of AF (0-2) ERAF (1) NPAF (1) LA area >21 cm2 (1) Common PV truncus (1) AF history >3 years (1) Female sex (1) NPAF (1) Normalized LA area ≥10.25 (1) GFR <68 mL/min (1) Metabolic syndrome (1) Cardiomyopathy (1) Age >65 years (1) NPAF (1) eGFR <60 mL/min/1.73 m2 (1) LAD ≥43 mm (1) LV EF <50% (1) Age >60 years (1) NPAF (2) LA volume/m2 (1 point per 10 mL/m2) Female sex (4) Current smoking (7) BMI >28 kg/m2 (1) LAD >40 mm (1) Current smoking (1) ERAF (1) AF history >6 years (1) NPAF (1) Coronary disease (1) LAD (0–4) Age (0–3) NPAF (2) AADs failed (0–2) Female sex (1) Diabetes (1) eGFR <90 mL/min/1.73 m2 (1) NPAF (1) LAD >45 mm (1) Age >65 years (1) Female sex (1) Hypertension (1) Male sex (1) BBB (1) LAD ≥47 mm (1) Type of AF (0-2) ERAF (1) NPAF (1) LA area >21 cm2 (1) Common PV truncus (1) AF history >3 years (1) Female sex (1) AAD, antiarrhythmic drug; AF, atrial fibrillation; AUC, area under curve; BBB, bundle branch block; BMI, body mass index; CA, catheter ablation; CFAE, complex fragmented atrial electrograms; CI, confidence interval; ERAF, early recurrence of atrial fibrillation; GFR, glomerular filtration rate; IQR, interquartile range; LA, left atrium; LAD, left atrial diameter; LVEF, left ventricular ejection fraction; MI, mitral isthmus; NA, not available; NPAF, non-paroxysmal atrial fibrillation; PAF, paroxysmal atrial fibrillation; PV, pulmonary vein; PVI, pulmonary vein isolation; RF, radiofrequency; SVCi, superior vena cava isolation. Common components of all of these scores that could be crucial for predicting AF recurrence post-CA are: LA enlargement, non-paroxysmal AF, and heart failure, Table 1.4,5 However, it should be emphasized that whilst these scores offer the risk stratification for recurrent AF post-CA, the final decision on CA (or a more conservative strategy) should be based on comprehensive clinical judgement, taking into account all potential benefits and harms of the procedure for each individual patient.1 Since AF ablation and follow-up strategies as well as the patient cohorts considerably differ among EP centres,1 future studies are needed to prospectively validate and compare all these scores in independent external cohorts in order to determine their relative predictive ability for post-CA recurrence and establish their applicability in everyday clinical practice. Conflict of interest: none declared.
No takes yet. Share an insight, caveat, or question.
Mujović et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: